The phenotype of gut endocrine tumours

被引:4
作者
Rindi, G
Ubiali, A
Villanacci, V
机构
[1] Univ Parma, Dept Pathol & Lab Med, I-43100 Parma, Italy
[2] Univ Brescia & Spedali Civili, Pathol Serv 2, Brescia, Italy
关键词
chromogranin A; endocrine cells; gut; immunohistochemistry; MEN1; NSE; pancreas; PGP9.5; synaptophysin;
D O I
10.1016/j.dld.2003.11.010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Endocrine turnouts of gut and pancreas tract are rare entities originating from cells of the diffuse endocrine system. The endocrine phenotype is assessed by the expression of general and specific endocrine markers. General endocrine markers associate to organelles like large dense core vesicles (e.g. chromogranin A) and small synaptic-like vesicles (e.g. synaptophysin), or to the cytosol, like neuron specific enolase and protein gene product 9.5 (PGP9.5). The specific markers correspond to the hormones produced by tumour cells. Two major categories of endocrine tumours are identified as (i) well-differentiated and (ii) poorly differentiated neoplasms. Well-differentiated tumours/carcinomas (also known as carcinoids) express all general markers of endocrine differentiation and various hormones. Poorly differentiated endocrine carcinomas lack large dense core vesicles markers (chromogranin A), while widely express synaptophysin and cytosol endocrine markers. The clinical behaviour of endocrine turnouts spans from benign to low-grade malignant for well-differentiated tumours/carcinomas to high grade malignant for poorly differentiated carcinomas. The Multiple Endocrine Neoplasia type I syndrome (MEN1) gene is involved in the genesis of a proportion of both well- and poorly differentiated sporadic turnouts. p53 gene abnormality appears as restricted to poorly differentiated endocrine carcinomas. (C) 2003 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:S26 / S30
页数:5
相关论文
共 56 条
[1]  
[Anonymous], RECENT ADV PATHOPHYS
[2]  
Beghelli S, 1998, J PATHOL, V186, P41, DOI 10.1002/(SICI)1096-9896(199809)186:1<41::AID-PATH172>3.0.CO
[3]  
2-L
[4]  
BISHOP AE, 1982, GASTROENTEROLOGY, V83, P902
[5]   Positional cloning of the gene for multiple endocrine neoplasia-type 1 [J].
Chandrasekharappa, SC ;
Guru, SC ;
Manickam, P ;
Olufemi, SE ;
Collins, FS ;
EmmertBuck, MR ;
Debelenko, LV ;
Zhuang, ZP ;
Lubensky, IA ;
Liotta, LA ;
Crabtree, JS ;
Wang, YP ;
Roe, BA ;
Weisemann, J ;
Boguski, MS ;
Agarwal, SK ;
Kester, MB ;
Kim, YS ;
Heppner, C ;
Dong, QH ;
Spiegel, AM ;
Burns, AL ;
Marx, SJ .
SCIENCE, 1997, 276 (5311) :404-407
[6]   A STUDY OF BIOLOGICAL BEHAVIOR BASED ON THE EXPRESSION OF A PROLIFERATING ANTIGEN IN NEUROENDOCRINE TUMORS OF THE DIGESTIVE-SYSTEM [J].
CHAUDHRY, A ;
OBERG, K ;
WILANDER, E .
TUMOR BIOLOGY, 1992, 13 (1-2) :27-35
[7]  
CHEJFEC G, 1985, CANCER, V56, P2683, DOI 10.1002/1097-0142(19851201)56:11<2683::AID-CNCR2820561127>3.0.CO
[8]  
2-L
[9]   Different patterns of 11q allelic losses in digestive endocrine tumors [J].
D'Adda, T ;
Pizzi, S ;
Azzoni, C ;
Bottarelli, L ;
Crafa, P ;
Pasquali, C ;
Davoli, C ;
Corleto, VD ;
Delle Fave, G ;
Bordi, C .
HUMAN PATHOLOGY, 2002, 33 (03) :322-329
[10]  
D'Adda T, 1999, LAB INVEST, V79, P671